Status:

WITHDRAWN

Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery

Lead Sponsor:

University of Sao Paulo

Conditions:

Circulatory Shock

Non-cardiac Surgery

Eligibility:

All Genders

18+ years

Phase:

PHASE2

PHASE3

Brief Summary

The purpose of the present study is to evaluate the effect of vasopressin compared to norepinephrine on the clinical complications of patients with vasospastic shock after noncardiac surgeries.

Detailed Description

The Systemic Inflammatory Response Syndrome (SIRS) is a common complication after non-cardiac surgery, impacting negatively on patient outcome and with high incidence rates. Vasoplegic syndrome is the...

Eligibility Criteria

Inclusion

  • Age greater than 18 years;
  • Patients undergoing high-risk non-cardiac surgery;
  • vasopressor need within 24 hours after surgery, defined as mean arterial pressure (MAP) \<65 mmHg after volume resuscitation with at least 1 liter of crystalloid solution (Ringer's lactate) and maintaining a cardiac index\> 2.2 ml / min / m²;
  • Signature of the informed consent form.

Exclusion

  • Allergy to vasoactive drugs;
  • Previous use of vasopressor;
  • Gestation;
  • Presence of Raynaud's phenomenon, altered Allen's test, systemic sclerosis or vasospastic diathesis;
  • Severe hyponatremia (Na \<130 mEq / L);
  • Acute mesenteric ischemia;
  • Acute coronary syndrome;
  • Participation in another study;
  • Refusal to participate in the study.

Key Trial Info

Start Date :

January 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 2 2023

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03483753

Start Date

January 1 2019

End Date

October 2 2023

Last Update

October 5 2023

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.